Strides Pharma Science
Strides Pharma Science Limited, commonly referred to as Strides, is a prominent player in the global pharmaceutical industry, headquartered in Bengaluru, India. Founded in 1990, the company has established a strong presence in various operational regions, including North America, Europe, and Africa. Strides focuses on the development, manufacturing, and marketing of a diverse range of pharmaceutical products, particularly in the areas of generic medications, complex generics, and over-the-counter (OTC) products. With a commitment to quality and innovation, Strides has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust pipeline of products. The company is recognised for its unique offerings in the injectable and oral dosage forms, positioning itself as a trusted partner in the healthcare sector. Strides Pharma Science continues to strengthen its market position through strategic collaborations and a dedication to meeting the evolving needs of patients worldwide.
DitchCarbon Score
How does Strides Pharma Science's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Strides Pharma Science's score of 34 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Strides Pharma Science's reported carbon emissions
In 2024, Strides Pharma Science reported total carbon emissions of approximately 53,760,000 kg CO2e for Scope 1, 17,099,000 kg CO2e for Scope 2, and 47,827,000 kg CO2e for Scope 3. In 2023, the company recorded emissions of about 5,331,800 kg CO2e for Scope 1 and 19,893,050 kg CO2e for Scope 2. The emissions data indicates a significant reliance on Scope 3 emissions, which are often the largest component for pharmaceutical companies. Strides Pharma Science is actively formulating a long-term decarbonisation strategy aimed at contributing to the global Net Zero agenda, with a target timeframe extending to 2050. This strategy encompasses both Scope 1 and Scope 2 emissions, reflecting the company's commitment to reducing its carbon footprint. The company has not yet disclosed specific reduction targets or achievements, nor does it appear to have cascaded data from a parent organisation. However, the ongoing efforts to develop a comprehensive decarbonisation roadmap signify a proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 6,168,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 19,385,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Strides Pharma Science is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
